Skip to main content
Back to OrbiMed

OrbiMed's Life Science Portfolio

Browse 15 Life Science companies funded by OrbiMed. See funding amounts, founder contacts, and investment details.

Life Science Companies
15
Total Funding in Life Science
$906.8M

Life Science Portfolio Companies (15)

Export
BiopharmaBiotechnologyLife ScienceOncology

Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.

Pacific Palisades, United States
May 2026
Post-IPO Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.

San Diego, United States
April 2026
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceMedicalPrecision Medicine

Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.

Watertown, United States
September 2025
$200.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceTherapeutics

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.

Cambridge, United States
March 2025
$50.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceMedicalWellness

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

Hellerup, Denmark
October 2023
$57.4M
Venture - Series Unknown

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyLife ScienceMedicalTherapeutics

Evozyne is a generative AI company that focuses on therapeutic discovery and drug development.

Chicago, United States
September 2023
$81.0M
Series B

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyLife Science

CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.

London, United Kingdom
April 2023
$20.0M
Venture - Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.

San Francisco, United States
November 2025
$185.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyLife ScienceMedicalTherapeutics

Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins.

Shanghai, China
December 2025
$30.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyLife SciencePharmaceutical

TELA Bio is a life science company that specializes in soft tissue reconstruction.

Malvern, United States
November 2025
$60.0M
Post Ipo Debt

Founder Contacts

19,000+ verified contacts

BiotechnologyLife ScienceTherapeutics

Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.

Berkeley, United States
July 2025
$54.5M
Seed

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife SciencePharmaceutical

Forte Biosciences is a biotechnology company that focuses on dermatology.

Sherman Oaks, United States
June 2025
$75.0M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceTherapeutics

Stratus Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.

Cambridge, United States
March 2025
$50.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife Science

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.

Cambridge, United States
January 2025
$3.9M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareLife ScienceNeuroscienceTherapeutics

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

Cambridge, United States
June 2024
$40.0M
Post Ipo Equity

Founder Contacts

19,000+ verified contacts

Explore OrbiMed's Full Portfolio

View all companies funded by OrbiMed across every industry and funding stage.

View Full OrbiMed Portfolio